

NDA 020165/S-050

SUPPLEMENT APPROVAL

Chattem, Inc. d/b/a Sanofi Consumer Healthcare
Attention: Disha Shah
Regulatory Compliance & Ops Manager
55 Corporate Drive
Bridgewater, NJ 08807

Dear Disha Shah:

Please refer to your supplemental new drug application (sNDA) dated and received July 25, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nicoderm CQ (nicotine transdermal system) extended release film, 7mg/24 hr, 14 mg/24 hr, 21 mg/24 hr.

This “Prior Approval” sNDA provides for an update to the storage conditions from 20-25°C to 15-25°C and updates to the principal display panel design.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be in the “Drug Facts” format (21 CFR 201.66), where applicable, and identical to the following:

Submitted Labeling Description	Submission Date
7 mg, 14 count Retail Carton	September 27, 2024
7 mg, 14 count Non-Retail Carton	September 27, 2024
14 mg, 14 count Retail Carton	September 27, 2024
14 mg, 14 count Non-Retail Carton	September 27, 2024
14 mg, 21 count Retail (Club) Carton	September 27, 2024
21 mg, 3 count Sample Carton	September 27, 2024
21 mg, 7 count Retail Carton	September 27, 2024
21 mg, 14 count Retail Carton	September 27, 2024
21 mg, 14 count Non-Retail Carton	September 27, 2024
21 mg, 21 count Retail (Club) Carton	September 27, 2024
7 mg, immediate container (pouch)	September 27, 2024

14 mg, immediate container (pouch)	September 27, 2024
21 mg, immediate container (pouch)	September 27, 2024
User Guide (leaflet)	September 27, 2024

(b) (4)

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 020165/S-050.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, call Cynthia Kim, PharmD, BCPS, Senior Regulatory Project Manager, at 301-796-0879.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
11/06/2024 03:59:14 PM